Thyroid management
The most common mistake in midlife thyroid care is treating a slightly high thyroid-stimulating hormone (TSH) reading in someone who feels perfectly well. The biggest recent shift is the recognition that most "thyroid cancers" picked up on neck ultrasound would never have caused any harm.
The classical model of thyroid disease was tidy: hypothyroid, hyperthyroid, or normal. The 2017–2026 evidence has dismantled the borders. The reference range itself is being rewritten by age, sex, and biology. The landmark RCT in older adults with subclinical hypothyroidism showed no benefit from treatment. A protective high-TSH phenotype keeps showing up in centenarian cohorts. A meaningful fraction of patients on the standard levothyroxine monotherapy still feel hypothyroid even when their bloodwork is "perfect," and nobody yet knows why; an early genetic explanation has not held up. And the global thyroid cancer "epidemic" turned out to be an iatrogenic artifact of high-resolution ultrasound. This article walks the calibrated reading.
The TSH reference-range argument (Moderate)
The standard adult TSH reference range — roughly 0.45–4.5 mIU/L — comes mostly from the third US National Health and Nutrition Examination Survey (NHANES III). The statistical objection is that the population it was drawn from included people with undiagnosed autoimmune thyroid disease, which inflates the upper end. Filter out positive thyroid antibodies, goiters, and family history, and the upper limit of "truly disease-free" sits closer to 2.5–3.0 mIU/L.[1]
The clinical objection runs the other way. Surks and colleagues estimated that universally adopting 3.0 mIU/L as the cutoff would reclassify 22–28 million Americans as having subclinical hypothyroidism overnight — and trigger a wave of levothyroxine prescriptions whose long-term mortality, cognitive, and cardiac benefits aren't there in the data.[2] The risks on the other side are real. In a large Dutch primary-care cohort, a suppressed TSH, whatever the cause, was linked to about 37% more atrial fibrillation (hazard ratio 1.37),[3] and over-replacement also speeds bone loss. In people over 65, a TSH pushed low by too much thyroid hormone was linked to about 34% more new cognitive impairment and dementia (adjusted hazard ratio 1.34).[4] Overtreatment is common: more than half of new levothyroxine prescriptions at three US academic centres did not meet evidence-based criteria.[5]
The newer and more useful reframe is demographic-specific intervals. A 2025 Annals of Internal Medicine analysis combining NHANES (8,308 US adults) with a 314,302-person Chinese cohort showed the 97.5th percentile of TSH rises with age and varies across racial and ethnic groups, while total thyroxine (T4) stays largely stable with age and women run slightly higher than men.[6] Applying these intervals reclassifies 48.5% of people previously labeled subclinically hypothyroid as normal, and 31.2% of those previously labeled subclinically hyperthyroid. The French Endocrine Society's heuristic for older adults — divide age by 10 to set the upper limit of normal, so 7.0 mIU/L at age 70 — captures the same intuition without requiring a population-genetics workup.[7]
The practical version: a TSH of 4.5 in a 70-year-old is not the same number as a TSH of 4.5 in a 30-year-old, and shouldn't trigger the same response.
Subclinical hypothyroidism — what TRUST settled (Strong)
The defining trial in geriatric thyroid care is TRUST, an RCT of 737 community-dwelling adults aged ≥65 with persistent subclinical hypothyroidism (TSH 4.60–19.99 mIU/L on two measurements; normal free T4) randomized to levothyroxine vs placebo, titrated to a normal TSH.[8]
Levothyroxine produced no improvement in:
- Hypothyroid symptoms (on ThyPRO, a thyroid-specific quality-of-life questionnaire)
- Vitality / fatigue
- Executive cognitive function
- Handgrip strength
- Activities of daily living
- Carotid intima-media thickness
- Fatal or non-fatal cardiovascular events (no difference, but with few events over about 18 months the trial was not powered to detect one)
A separate longitudinal observation strengthens the case for restraint: among 1,751 people with subclinical hypothyroidism followed at a health-screening centre, 57.9% reverted to euthyroid over a median 36 months with no intervention at all.[9] That study's main finding explains part of why: TSH swings with the seasons, running higher in winter and spring and lower in summer and autumn, and a repeat test in summer or autumn was about 1.4 times more likely to come back normal. Most of what gets labeled subclinical hypothyroidism on a single lab in an older adult isn't a disease in progress — it's noise, or a transient illness response, or an age-appropriate drift. The same holds in people over 65: in the TRUST and IEMO80+ trial populations, TSH returned to normal within about a year in 61% of older adults after one high reading, and in 40% of those already confirmed high on two tests at least three months apart. A lower starting TSH, negative TPO antibodies and a summer retest made normalization more likely, and the authors suggest a third test before starting treatment.[10]
The corollary: don't treat a slightly elevated TSH in a well person. Guidelines carve out exceptions, but most rest on convention rather than trials. Pregnancy is the clearest case, and even there the trial evidence is thin: in a meta-analysis of trials, levothyroxine during pregnancy may have lowered preterm births when TSH was above 4 mIU/L, but that result on its own was not statistically clear; treating before conception did not raise live-birth rates.[11] Many clinicians also treat a TSH that stays above 10 mIU/L, or clearly symptomatic younger adults, but the BMJ guideline panel's strong recommendation against treatment excludes only women trying to conceive, people with TSH above 20 mIU/L, and possibly people with severe symptoms or aged 30 or younger.[12] The default is recheck-and-watch, not prescribe.
The centenarian phenotype and the longevity inverse (Moderate)
A counter-intuitive finding shows up across longevity cohorts: people who live extraordinarily long lives tend to run a higher TSH, not lower. In an Ashkenazi centenarian cohort, the TSH frequency curve was shape-similar to younger controls but shifted right — 35.2% of centenarians had a TSH above 2.5 mIU/L vs 15.4% of controls.[13] A companion study in the same cohort found the pattern extends to the centenarians' offspring, pointing to an inherited component in the set point of the hypothalamic–pituitary–thyroid (HPT) axis.[14]
Data from the Rotterdam Study point the same way, but only within the normal range. Among about 7,800 adults whose thyroid tests were all normal, those with a TSH in the top third of normal lived about 2.0 years (men) and 1.4 years (women) longer from age 50 than those in the bottom third, and those with free T4 in the top third of normal lived about 3.2 years (men) and 3.5 years (women) less. Much of the difference was in years free of cardiovascular disease.[15]
The mechanistic case sits on the "rate of living" framework. Triiodothyronine (T3) turns up the mitochondrial proteins that deliberately let energy escape as heat instead of capturing it as usable fuel — thermogenesis bought at metabolic cost.[16] The byproduct is reactive oxygen species, the corrosive molecules thrown off as a side-effect of burning fuel; the cumulative downstream is oxidative DNA damage, telomere shortening, and accelerated cellular senescence. Slightly downregulating the axis decelerates the engine — fewer of those reactive byproducts per unit time, less compounding damage over decades.
The healthspan-vs-lifespan catch
This is exactly not an argument for chasing low thyroid function. The Pax8+/− mouse model — a stable mild genetic hypothyroid state — lives a normal lifespan but with severe insulin resistance, hepatic steatosis, and elevated rates of aggressive liver cancer.[17] Profound metabolic suppression buys lifespan at the cost of healthspan. The implication for humans is narrow: a mildly elevated TSH in an aging adult is adaptive and probably protective; deliberately suppressing thyroid function below the normal range to mimic the centenarian phenotype isn't a strategy; in those mice it looked like metabolic syndrome in slow motion.
Levothyroxine monotherapy and residual symptoms (Moderate)
Synthetic levothyroxine (LT4) has been the global standard for over half a century. It works by being converted at the cellular level — by the deiodinases DIO1 and DIO2 — into biologically active T3. The assumption is that a normal serum TSH on LT4 equals adequate T3 at the tissues.
Roughly 5–15% of LT4-treated patients with a biochemically normalized TSH report persistent residual symptoms. Among those who do, the complaints cluster tightly: energy and fatigue (reported by 80–90%), weight management (70–75%), memory (60–80%), and mood (40–50%).[18] After ruling out the usual confounders (iron deficiency, B12, sleep apnea, depression, occult autoimmune disease), the leading (unproven) explanation is localized tissue hypothyroidism: enough T4 in the blood, not enough conversion to T3 where it matters.[19]
A native thyroid secretes T4 and T3 in roughly a 14:1 ratio. Patients on LT4 alone tend to run a lower serum T3/T4 ratio than non-treated euthyroid controls, and a depressed ratio tracks with classical hypothyroid complaints.[20] The best-studied genetic candidate is the DIO2 Thr92Ala polymorphism, a common variant in the enzyme that makes T3 inside tissues. An early secondary analysis of one trial suggested that people with two copies felt worse on LT4 and improved more when T3 was added, and the authors said it needed replication.[21] Later studies did not confirm it: in a double-blind crossover trial of 75 patients the genotype made no difference to response,[22] and among nearly 19,000 LT4-treated UK Biobank participants, carriers had no worse well-being or cognition than non-carriers.[23] It remains a plausible mechanism, not a proven predictor.
What combination therapy actually delivers
A 2024 meta-analysis of 16 randomized trials — 15 of LT4 + LT3 combination therapy against LT4 alone, plus two of desiccated thyroid (the paper's own counts, which sum to 17, so at least one trial tested both) — found measurable biochemical changes (free T4 down, total T3 up) and a statistically significant improvement on the General Health Questionnaire (GHQ-28) — about 3 points of a 28-item distress score, a real but modest shift.[24] The picture is otherwise mixed: fatigue scales, lipids, resting heart rate, and generic quality-of-life metrics often don't separate. Pharmacokinetics is part of the problem — oral liothyronine has a short half-life, producing a supraphysiological serum-T3 spike a few hours after a dose and an afternoon trough. Multidaily dosing helps; sustained-release formulations would help more and aren't widely available.
Desiccated thyroid extract (DTE; e.g., Armour Thyroid, NP Thyroid) contains both T4 and T3 in an animal-derived ~4:1 ratio. Patient satisfaction often runs high (likely the morning T3 surge), and the same 2024 meta-analysis showed higher serum total T3 and slightly higher TSH compared to LT4 monotherapy — but the trial quality remains low, and DTE's ratio is non-physiological for humans.[25]
When to consider combination therapy. Persistent, well-characterized symptoms despite a normal TSH, after other causes have been ruled out. The European Thyroid Association treats it as a supervised experiment: a specialist starts it at an LT4:LT3 ratio of about 13:1 to 20:1 by weight, with the LT3 split into two daily doses, and stops it if nothing improves after 3 months.[26] DIO2 genotyping is a research tool, not a clinical test; the American Thyroid Association recommends against using genetic testing to choose therapy.[27] Target a near-physiological T3/T4 ratio and monitor TSH closely so it isn't suppressed; over-replacement is what drives atrial fibrillation and bone loss. At correct doses the safety data are broadly reassuring. In pooled trials, adverse events were not clearly more common on LT4+LT3 than on LT4 alone (relative risk 1.22, 95% CI 0.66–2.25), and in observational cohorts of over 600,000 people, LT3 users showed no significant increase in atrial fibrillation (relative risk 1.10, 95% CI 0.74–1.63), though the heart-failure estimate was borderline. The serious harms in case reports came from unregulated or compounded T3.[28] It is not a generic upgrade over monotherapy for the asymptomatic patient with a normal TSH.
Hashimoto's — the autoimmune layer beneath most hypothyroidism (Moderate)
In iodine-sufficient countries, the overwhelming majority of primary hypothyroidism is downstream of Hashimoto's thyroiditis — chronic autoimmune destruction of the gland, marked by antibodies against thyroid peroxidase (TPOAb) and thyroglobulin (TGAb). Women are affected 4–10 times more often than men.[29] The standard-of-care moment for intervention has historically been after the gland fails — i.e., once levothyroxine becomes necessary. The expanding evidence base asks whether upstream levers can move that trajectory; so far they shift antibody levels more than outcomes.
Selenium — the strongest nutritional signal
The thyroid is one of the most selenium-rich tissues in the body, though in an autopsy study of 133 adults the kidney and the pituitary gland held more per gram. The body ranks its organs for selenium supply and protects the thyroid when intake runs low.[30] Selenium is the catalytic core of the deiodinases and glutathione peroxidases that neutralize the hydrogen peroxide thyroid hormone synthesis generates. Selenium deficiency leaves follicular cells exposed to oxidative damage and accelerates autoantigen release.
The largest meta-analysis — 35 randomized trials, graded moderate-certainty — found that supplemental selenium produced a moderate-to-large reduction in thyroid peroxidase antibodies (standardized mean difference −0.96, 95% confidence interval −1.36 to −0.56) and lowered TSH in patients not already taking levothyroxine. The antibody effect held whether or not patients were on replacement. Thyroglobulin antibodies did not change significantly.[31] (That bracketed range is a 95% confidence interval — the span where the true effect most plausibly lies. When such a range crosses zero for a difference, or 1.0 for a ratio, the finding is compatible with no real effect.) A 2025 meta-analysis agrees on direction and adds a durability caveat: thyroglobulin antibodies fell at three months but not at six.[32]
Typical trial doses run 50–200 µg/day. The therapeutic window is narrow. Europe's food-safety agency puts the safe upper limit for adults at 255 µg a day from all sources, food and supplements combined (the US limit is 400 µg a day). That figure sits a margin below 330 µg a day, the lowest total intake at which extra hair loss appeared in a large trial; chronic excess also brings brittle nails and digestive upset.[33] Two Brazil nuts a day raise selenium status about as well as a 100 µg supplement, but their content varies a lot: in one trial two nuts delivered 20–84 µg (53 µg on average).[34] If you already eat Brazil nuts regularly, don't add a selenium supplement on top.
Selenium has the most robust antibody-lowering data of any nutritional intervention in this disease, but lower antibodies have not translated into feeling better. In the largest trial with a patient-centred outcome, 412 people already on levothyroxine took 200 µg selenium or placebo daily for a year. Quality of life improved equally in both groups, including in those who started with low selenium, and the small drop in antibodies did not change how much levothyroxine they needed.[35] No trial has shown that selenium delays the need for levothyroxine.
Vitamin D — worth correcting if low, little proof beyond that
Vitamin D promotes the regulatory T cells that hold autoimmunity in check and damps down the inflammatory arms of the immune response. Deficiency tracks with higher antibody titers, but the dose-response is non-linear: high-dose pulse regimens correct blood vitamin D and normalize TSH, but the antibody response plateaus quickly.[36] Pooled trials are inconsistent. One 2024 network analysis found no clear antibody drop versus placebo over six months.[37] Another pooled before-and-after changes from 10 trials in autoimmune thyroid disease and found that TPO antibodies fell only in people who started low in vitamin D, with larger falls after at least three months and with daily rather than weekly dosing.[38] Variants in the vitamin D receptor gene may change the response, but that evidence comes from small case-control studies, not trials.[39] The practical reading: correct a low level (below 50 nmol/L, 20 ng/mL); no trial shows that extra vitamin D changes the course of the disease.
What else helps and what doesn't
- Omega-3 fatty acids — higher red-blood-cell levels of alpha-linolenic acid (ALA) and eicosapentaenoic acid (EPA) associate with roughly 26–37% lower odds of Hashimoto's (odds ratios 0.63 for ALA and 0.74 for EPA).[40] This is cross-sectional, so it establishes association, not protection. Mechanism is anti-inflammatory membrane remodeling. See Omega-3.
- Lactose restriction if you are lactose-intolerant — in one small uncontrolled study, 38 lactose-intolerant Hashimoto's patients on levothyroxine who cut out lactose for 8 weeks saw TSH fall (for example from about 5.5 to 2.3 mIU/L in the 8 with subclinical hypothyroidism), probably because their levothyroxine was absorbed better.[41] Absorption itself was not measured and there was no randomized control group. Worth considering if your dose keeps creeping up or your TSH is erratic.
- The autoimmune protocol (AIP), grain-free and gluten-free diets — popular, but unproven. In one small uncontrolled study of 28 people with Hashimoto's, symptoms eased on AIP over 12 weeks, but thyroid tests did not clearly improve and TPO antibodies rose.[42] A 2025 meta-analysis pooling three randomized trials of gluten-free diets in people with Hashimoto's but without celiac disease found no effect on TSH, thyroid hormones or CRP, and mixed antibody results (anti-thyroglobulin slightly lower, anti-TPO higher), at very low certainty.[43] Go gluten-free if you have celiac disease; otherwise treat these diets as optional.
- Myo-inositol — unproven. A network analysis found no clear antibody benefit versus placebo, with very wide uncertainty.[44] In three small trials (288 people) of Hashimoto's with mildly raised TSH, adding myo-inositol to selenium lowered TSH more than selenium alone, without changing TPO antibodies.[45] Interesting, but too thin to recommend.
Iodine — a U-shaped curve, not a "more is better" nutrient (Strong)
Iodine is the obligate elemental substrate for T4 and T3 synthesis. Both deficiency and excess disrupt thyroid function; the dose-response is bimodal.
The cleanest natural experiment is the Randers-Skagen 20-year cohort in Denmark, comparing two communities with vastly different drinking-water iodine: Skagen at 139 µg/L (urinary iodine ~160 µg/L, optimal), Randers at 2 µg/L (urinary ~55 µg/L, mild–moderate deficiency).[46] At baseline (participants aged 75–80), 26% of people in the iodine-deficient town had a TSH below the normal range, a marker of an overactive thyroid that includes mild (subclinical) cases, against 6% in the replete town. Hypothyroidism ran the other way: 13% in the replete town versus 6%.[47] That fits a gland short of iodine compensating by growing nodules that make hormone on their own. After 20 years, mortality in the iodine-replete cohort was about 40% lower (adjusted HR 0.60, 95% CI 0.41–0.87). The cohorts were small — 428 people followed to the end — so treat the size of the effect as indicative rather than precise.
The other side of the curve matters too. Ingesting more than the ~1,100 µg/day tolerable upper limit — easy to do with kelp supplements or Lugol's solution — can break the Wolff-Chaikoff autoregulatory escape, especially in aging glands or those with silent autoimmunity, producing iatrogenic iodine-induced hypothyroidism.[48] The American Thyroid Association recommends against chronic supplementation above 500 µg/day; the recommended daily allowance for non-pregnant adults is 150 µg/day, and 220–290 µg in pregnancy and lactation.
| Iodine intake | Effect |
|---|---|
| Severe/moderate deficiency (<100 µg/d) | Goiter, hyperthyroidism via autonomous nodules, fetal neurodevelopmental harm |
| Sufficient (about 150–290 µg/d) | Normal hormone synthesis; in one small Danish cohort, older adults in an iodine-replete town lived longer than those in a mildly-to-moderately deficient one |
| Excess (supplements above ~500 µg/d; adult upper limit 1,100 µg/d) | Iodine-induced hypothyroidism, especially in older people or those with existing thyroid disease |
Practical version: adults need about 150 µg of iodine a day, and dairy, fish, eggs and iodized salt are the main sources. Where intake depends on food choice rather than fortified salt, it is fragile: it drops when people cut back on salt or move to plant-based diets, and it matters before pregnancy as well as during it.[49] In one 2024 study of young Norwegians, vegans' median urinary iodine was under 50 µg/L, in the moderate-deficiency range.[50] If you eat little dairy or fish, use iodized salt at home or a supplement of about 150 µg. Check the label: not every multivitamin contains iodine. Kelp and Lugol's-style megadosing is one of the easier ways to cause the disease they're marketed against.
The thyroid cancer overdiagnosis epidemic (Caution)
The thyroid cancer story is now the canonical case study in screening-driven overdiagnosis. US papillary thyroid cancer incidence nearly quadrupled, from 3.4 to 12.5 per 100,000 between 1975 and 2009, while thyroid cancer deaths held at about 0.5 per 100,000.[51] Since about 2014 the trend has reversed: thyroid cancer incidence fell by about 2% a year through 2018, fastest among tumours of 1 cm or less (about 6% a year), while tumours over 2 cm held steady. That is the pattern expected when doctors stop finding harmless tumours, not when the disease itself becomes rarer. Deaths among diagnosed patients still rose by about 1% a year from 2000 to 2018, a reminder that a small share of these cancers are not harmless.[52] Microsimulation modeling estimates that 72% to 94% of all US papillary thyroid cancer diagnoses between 1991 and 2019 were overdiagnoses — clinically silent, indolent tumors that would never have caused symptoms.[53] The burden fell disproportionately on women: an estimated 13–17 overdiagnosed cases per 100,000 women per year, against 3–5 per 100,000 men, largely because women get more neck imaging.
The driver was the proliferation of high-resolution neck ultrasonography in primary care, combined with fine-needle aspiration of subcentimeter nonpalpable nodules. The downstream cost was several hundred thousand overdiagnosed cancers, many followed by thyroidectomy, radioactive iodine and lifelong levothyroxine — plus the surgical risks of recurrent laryngeal nerve injury and permanent hypoparathyroidism — for a "cancer" that was never going to do harm. The crossover with cancer screening is direct: the same length-time bias logic that complicates DCIS and PSA findings applies here, and harder. Because screening ultrasound drives this overdiagnosis, the US Preventive Services Task Force recommends against screening adults without symptoms for thyroid cancer, whether by neck exam or ultrasound (grade D, still current).[54] Unless you have a specific risk factor (radiation to the head or neck in childhood, or a strong family history or inherited syndrome) or a lump, hoarseness or swallowing trouble, a "screening" thyroid ultrasound is more likely to start a cascade than to help.
The 2025 American Thyroid Association (ATA) guidelines for differentiated thyroid cancer brought active surveillance into the guideline itself as an option that may be offered to selected patients with cT1aN0M0 (≤1 cm, no nodal involvement, no extrathyroidal extension) papillary thyroid cancer.[55] Worth being precise about the strength: this is a conditional recommendation resting on low-certainty evidence — a legitimate option to discuss, not an established standard that overrides surgery. The best long-term data come from Japan's Kuma Hospital, which has offered surveillance since 1993; 3,222 adults chose it. About 5% of tumours had grown by 3 mm or more at 10 years (about 7% at 20), about 1–2% developed new lymph-node spread, roughly 1 in 8 eventually chose or needed surgery, and nobody in the series died of thyroid cancer.[56] A 2025 review of surveillance at Kuma and a second Japanese hospital (running since 1995) likewise reports no thyroid-cancer deaths among patients under surveillance.[57] These are retrospective, self-selected groups, which is why the recommendation stays conditional. The same guideline adds a third route that may be considered for selected patients: ultrasound-guided ablation (usually radiofrequency), which destroys the tumour through a needle without removing the gland. This is also conditional; early results are good, but long-term data are thin and outcomes depend heavily on the operator's experience.[58][59] The surveillance protocol itself is austere on purpose:[60]
- Monitoring is by neck ultrasound, not biochemistry — routine thyroglobulin is explicitly not indicated.
- Surgical triggers are concrete: the tumour grows by 3 mm or more or grows toward the back of the gland, a biopsy confirms new lymph-node spread, distant spread or growth outside the thyroid appears, or the patient becomes too anxious, can't keep up follow-up, or simply prefers surgery.[61]
Separately, for advanced cancer that keeps growing and no longer responds to radioactive iodine, the guideline recommends a multikinase inhibitor when the tumour has no targetable genetic driver: lenvatinib (preferred, usually started at 24 mg once daily, with doses paused or reduced as needed for side effects) or sorafenib. Tumours with an NTRK or RET fusion should first get a drug aimed at that alteration.[62]
The framing matters beyond oncology. A patient told they have a tiny papillary cancer, and that watching it is a legitimate choice rather than an act of negligence, is being offered something a generation of patients didn't have — preservation of native thyroid function and freedom from lifelong synthetic replacement.
Practical guidance
- Test TSH when there's a reason — fatigue, weight change, mood, cold intolerance, hair changes, slow recovery, dyslipidemia, infertility evaluation, in pregnancy, or as a baseline at midlife. Don't make TSH a tracking biomarker for "optimization" — see the wider midlife lab cadence for where TSH does and doesn't belong on a screening panel. Recheck a single abnormal value in 6–12 weeks before treating.
- Interpret the result in context. A TSH of 4–6 mIU/L in a 65-year-old without symptoms is most likely physiological. The French "age divided by 10" upper limit captures the right calibration.
- Add antibodies when the picture is unclear — TPOAb and TGAb separate truly autoimmune disease from incidental drift. Antibody-positive patients deserve closer follow-up even if TSH is borderline.
- Don't treat subclinical hypothyroidism without a specific indication, especially in older adults. TRUST is the strongest single trial in the area; the answer was no benefit. Exceptions by convention are pregnancy or trying to conceive, a TSH that stays above 10 mIU/L, and clearly symptomatic younger adults — and even these rest more on clinical consensus than on trial evidence.
- If you're on levothyroxine and still feel hypothyroid with a normal TSH, rule out the usual confounders (iron, B12, sleep apnea, depression, insomnia, overtraining). If they're clean, a time-limited trial of LT4+LT3 at a physiological ratio with a thyroid specialist is reasonable — not first-line, but legitimate. In one crossover trial, people did equally well on LT4 or combination therapy as a group, but in a subgroup analysis the third with the most symptoms on LT4 alone preferred and did better on T3-containing therapy.[63] A DIO2 gene test isn't needed: the variant made no difference to outcomes in that trial.
- Get selenium from food rather than supplements, and correct a low vitamin D rather than chase a target. Fish, eggs, meat and the occasional Brazil nut supply selenium; nut content varies widely, so a daily handful is not needed. Don't take 100–200 µg selenium supplements by default: in people with Hashimoto's already on levothyroxine, 200 µg a day for a year lowered thyroid antibodies slightly but did not improve quality of life or change the levothyroxine dose,[64] and in pooled trials 200 µg a day raised the risk of type 2 diabetes by about 11% (relative risk 1.11).[65] For vitamin D, a 2024 Endocrine Society guideline for the general population found no clear evidence for an optimal blood level and advises against routine testing without a specific reason;[66] if a test does show a low level (below 50 nmol/L, 20 ng/mL), correcting it is reasonable (see Vitamin D).
- Get iodine from food, not megadose supplements. Iodized salt, seafood, dairy. Skip kelp tablets and Lugol's drops unless prescribed.
- If a scan turns up a small thyroid nodule, don't rush to biopsy or surgery. The 2025 ATA guideline says a needle biopsy is not routinely recommended for nodules of 1 cm or less that look low-risk on ultrasound. If a biopsy has already shown a papillary cancer of 1 cm or less, with no spread to lymph nodes and no growth outside the thyroid, ask whether active surveillance (regular ultrasound instead of immediate surgery) or ablation suits you. The guideline says surveillance may be offered to selected patients, a conditional recommendation on low-certainty evidence.[67] Korea's 2025 guideline limits it to biopsy-confirmed tumours.[68] It is a conversation to have, not a foregone conclusion either way.
What's overrated
- Pushing TSH into the "optimal" 0.5–2.0 range in an asymptomatic adult. The longevity inverse runs the other way.
- "Adrenal-thyroid fatigue" protocols combining desiccated thyroid, exogenous cortisol, and unvalidated saliva panels — none of which have RCT support, several of which carry real harms.
- Iodine megadosing, including kelp, Lugol's solution, and "thyroid support" formulas that exceed the tolerable upper limit.
- Reflex thyroidectomy for sub-centimeter papillary cancer. Since 2025, the ATA guideline lists active surveillance as an option that may be offered for selected papillary cancers of 1 cm or smaller confined to the thyroid with no spread (a conditional recommendation on low-certainty evidence), so automatic surgery is no longer the only defensible path.[69]
Further reading
- Stott DJ et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism (TRUST). NEJM 2017.[70]
- Atzmon G et al. Extreme Longevity Is Associated with Increased Serum Thyrotropin. JCEM 2009.[71]
- Bano A et al. Association of Thyroid Function with Life Expectancy: The Rotterdam Study. JAMA Intern Med 2017.[72]
- Li Q et al. Thyroid Function Reference Intervals by Age, Sex, and Race: A Cross-Sectional Study. Ann Intern Med 2025.[73]
- Kim TH et al. Effect of seasonal changes on the transition between subclinical hypothyroid and euthyroid status. JCEM 2013.[74]
- Nassar M et al. Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism — systematic review and meta-analysis. BMC Endocr Disord 2024.[75]
- Wiersinga WM. T4+T3 Combination Therapy: An Unsolved Problem of Increasing Magnitude and Complexity. Endocrinol Metab 2021.[76]
- Huwiler VV et al. Selenium Supplementation in Patients with Hashimoto Thyroiditis — systematic review and meta-analysis of randomized clinical trials. Thyroid 2024.[77]
- Francis DO et al. Overdiagnosis of Papillary Thyroid Cancer. JAMA Netw Open 2026.[78]
- Ringel MD et al. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid 2025.[79]
- Riis J et al. Long-term iodine nutrition is associated with longevity in older adults: a 20 years' follow-up of the Randers-Skagen study. Br J Nutr 2021 (epub 2020).[80]
- Goichot B et al. Management of thyroid dysfunctions in the elderly — French Endocrine Society consensus 2019 guidelines. Ann Endocrinol 2020.[81]